389 related articles for article (PubMed ID: 32922403)
1. Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings.
Goruganthu MUL; Shanker A; Dikov MM; Carbone DP
Front Immunol; 2020; 11():1958. PubMed ID: 32922403
[TBL] [Abstract][Full Text] [Related]
2. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
Front Immunol; 2018; 9():1288. PubMed ID: 29915603
[TBL] [Abstract][Full Text] [Related]
3. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
Galluzzi L; Buqué A; Kepp O; Zitvogel L; Kroemer G
Cancer Cell; 2015 Dec; 28(6):690-714. PubMed ID: 26678337
[TBL] [Abstract][Full Text] [Related]
4. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Reprogramming of CD4
Renaude E; Kroemer M; Borg C; Peixoto P; Hervouet E; Loyon R; Adotévi O
Front Immunol; 2021; 12():669992. PubMed ID: 34262562
[TBL] [Abstract][Full Text] [Related]
6. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches.
Klein K; He K; Younes AI; Barsoumian HB; Chen D; Ozgen T; Mosaffa S; Patel RR; Gu M; Novaes J; Narayanan A; Cortez MA; Welsh JW
Front Immunol; 2020; 11():573326. PubMed ID: 33178201
[TBL] [Abstract][Full Text] [Related]
7. Rationale for anti-CD137 cancer immunotherapy.
Makkouk A; Chester C; Kohrt HE
Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully.
Lin B; Du L; Li H; Zhu X; Cui L; Li X
Biomed Pharmacother; 2020 Dec; 132():110873. PubMed ID: 33068926
[TBL] [Abstract][Full Text] [Related]
9. NOTCH Signaling in T-Cell-Mediated Anti-Tumor Immunity and T-Cell-Based Immunotherapies.
Kelliher MA; Roderick JE
Front Immunol; 2018; 9():1718. PubMed ID: 30967879
[TBL] [Abstract][Full Text] [Related]
10. Notch Pathway: A Journey from Notching Phenotypes to Cancer Immunotherapy.
Monticone G; Miele L
Adv Exp Med Biol; 2021; 1287():201-222. PubMed ID: 33034034
[TBL] [Abstract][Full Text] [Related]
11. Precision medicine for human cancers with Notch signaling dysregulation (Review).
Katoh M; Katoh M
Int J Mol Med; 2020 Feb; 45(2):279-297. PubMed ID: 31894255
[TBL] [Abstract][Full Text] [Related]
12. Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes.
Allison KE; Coomber BL; Bridle BW
Immunology; 2017 Oct; 152(2):175-184. PubMed ID: 28621843
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulation in cancer.
Hegmans JP; Aerts JG
Curr Opin Pharmacol; 2014 Aug; 17():17-21. PubMed ID: 25011112
[TBL] [Abstract][Full Text] [Related]
14. Editorial: CD4
González-Navajas JM; Elkord E; Lee J
Front Immunol; 2021; 12():737615. PubMed ID: 34552596
[No Abstract] [Full Text] [Related]
15. Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy.
Lim EL; Okkenhaug K
Immunology; 2019 Jul; 157(3):210-218. PubMed ID: 31107985
[TBL] [Abstract][Full Text] [Related]
16. Rational targeting of Notch signaling in cancer.
Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
[TBL] [Abstract][Full Text] [Related]
17. Targeting Notch to target cancer stem cells.
Pannuti A; Foreman K; Rizzo P; Osipo C; Golde T; Osborne B; Miele L
Clin Cancer Res; 2010 Jun; 16(12):3141-52. PubMed ID: 20530696
[TBL] [Abstract][Full Text] [Related]
18. Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity.
Tchekneva EE; Goruganthu MUL; Uzhachenko RV; Thomas PL; Antonucci A; Chekneva I; Koenig M; Piao L; Akhter A; de Aquino MTP; Ranganathan P; Long N; Magliery T; Valujskikh A; Evans JV; Arasada RR; Massion PP; Carbone DP; Shanker A; Dikov MM
J Immunother Cancer; 2019 Apr; 7(1):95. PubMed ID: 30940183
[TBL] [Abstract][Full Text] [Related]
19. Editorial: Understanding Gamma Delta T Cell Multifunctionality - Towards Immunotherapeutic Applications.
Gustafsson K; Herrmann T; Dieli F
Front Immunol; 2020; 11():921. PubMed ID: 32477369
[No Abstract] [Full Text] [Related]
20. Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.
Khan AR; Dovedi SJ; Wilkinson RW; Pritchard DI
Int Rev Immunol; 2010 Oct; 29(5):461-84. PubMed ID: 20839911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
